Earnings ·
Clene Inc. reported a net loss of $13.4 million, or $1.08 per share, for the second quarter ended June 30, 2026…
CLNNWClene Inc.
Clene Inc. reported a net loss of $13.4 million, or $1.08 per share, for the second quarter ended June 30, 2026, compared to a $7.4 million loss in the prior year period. The company announced it expects to submit a New Drug Application (NDA) for its investigational therapy CNM-Au8 for amyotrophic lateral sclerosis (ALS) under the accelerated approval pathway in early Q4 2026, following FDA confirmation that proposed data may support such submission. Recent biomarker analyses indicated that patients with declining or stabilized neurofilament light levels experienced improved survival and functional outcomes. Financially, cash and cash equivalents stood at $9.7 million as of June 30, 2026, providing an operating runway through late Q4 2026. In May, Clene closed a registered direct offering for $7.0 million in gross proceeds and amended its convertible debt facilities to extend maturities to August 2027. The company operates as a late clinical-stage biopharmaceutical firm focused on developing therapies for neurodegenerative diseases.